Alnylam Pharmaceuticals ALNY Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $502.34M+318% | $278.1M+200% | $82.79M+125% | -$279.86M-284% | -$230.47M+30.6% | ||
| $54.81M-4.8% | $55.66M-1.8% | $56.32M+0.6% | $56.5M+2.1% | $57.56M+7.6% | ||
| $361.68M+27.6% | $348.24M+28.0% | $368.25M+65.6% | $305.84M+27.1% | $283.45M+24.8% | ||
| —— | —— | $603.72M— | $240.95M— | $94.39M— | ||
| —— | —— | -$23.18M+6.3% | -$24.13M-2.3% | -$19.78M-5.3% | ||
| —— | —— | —— | —— | —— | ||
| $98.06M+314% | $124.5M+3,956% | $28.23M— | $15.77M— | -$45.92M— | ||
| —— | —— | —— | -$58.56M-372% | -$51.83M-1,881% | ||
| -$27.25M+88.4% | -$52.94M+77.5% | -$65.75M+67.9% | -$56.34M+68.2% | -$234.2M-763% | ||
| —— | —— | —— | -$4.04M— | -$4.06M— | ||
| $714.9M+1,618% | $524.08M+6,405% | $265.86M— | -$15.54M— | -$47.11M— | ||
| $71.56M+136% | $58.7M+71.2% | $44.5M+9.9% | $36.55M-31.5% | $30.27M-50.6% | ||
| $1.17B-27.9% | $1.31B-20.2% | $1.56B-10.4% | $1.78B+2.9% | $1.62B-10.6% | ||
| $334.18M— | $473.5M— | $420.59M— | -$110.77M— | —— | ||
| $213.82M-34.5% | $250.03M-17.5% | $244.61M-17.8% | $274.9M+28.3% | $326.46M+149% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$319.51M-206% | $231.59M-0.5% | $311.33M+101% | ||
| —— | —— | —— | $39.39M+552% | $8.76M+257% | ||
| $690.17M— | $690.16M— | —— | —— | —— | ||
| $213.98M+103% | $218.71M+224% | $117.72M+94.0% | $109.97M+103% | $105.56M+115% | ||
| —— | —— | —— | —— | $15.34M+136% | ||
| —— | —— | —— | -$4.04M— | -$4.06M— | ||
| $98.06M+314% | $124.5M+3,956% | $28.23M— | $15.77M— | -$45.92M— | ||
| —— | $238.4M+87.5% | $210.58M+72.6% | $182.77M+56.4% | $154.95M+38.7% | ||
| —— | —— | $147.6M+23.5% | $137.46M+18.5% | $150.19M+33.1% | ||
| $59.78M— | $59.78M— | —— | —— | —— | ||
| $213.82M-34.5% | $250.03M-17.5% | $244.61M-17.8% | $274.9M+28.3% | $326.46M+149% | ||
| —— | $6M— | $4.5M— | $3M— | $1.5M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $3.28M— | ||
| $15.05M-82.5% | $59.78M-22.4% | $59.78M— | $77.28M— | $85.93M— | ||
| $12.66M-32.6% | $22.48M+131% | $13.67M+31.7% | $11.77M+29.6% | $18.78M+595% | ||
| —— | —— | —— | —— | $15.34M+136% | ||
| $643.34M+931% | $465.38M+1,193% | $221.36M— | -$52.09M— | -$77.38M— | ||
| $643.34M+931% | $465.38M+1,193% | $221.36M— | -$52.09M— | -$77.38M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alnylam Pharmaceuticals generate?
- Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
- What is Alnylam Pharmaceuticals's free cash flow?
- After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
- Where does Alnylam Pharmaceuticals's cash flow data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
